|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Stephen P. MacMillan||Chairman, CEO & Pres||4,51M||S.O.||1964|
|Ms. Karleen M. Oberton||Chief Financial Officer||1,6M||S.O.||1971|
|Mr. John M. Griffin||Gen. Counsel||1,56M||1,73M||1961|
|Mr. Kevin R. Thornal||Group Pres of Global Diagnostic Solutions||1,66M||595,56k||1974|
|Mr. Paul Malenchini||Chief Information Officer||S.O.||S.O.||S.O.|
|Ryan M. Simon||VP of Investor Relations||S.O.||S.O.||S.O.|
|Ms. Elisabeth A. Hellmann||Sr. VP of Global HR & Corp. Communications||S.O.||S.O.||1969|
|Mr. Jan Verstreken||Group Pres of International||S.O.||S.O.||1968|
|Ms. Monica Aguirre Berthelot||VP & Chief of Staff||S.O.||S.O.||S.O.|
|Mr. Mike Kelly||Chief Supply Chain Officer and Corp. VP of Quality Assurance & Regulatory Affairs||S.O.||S.O.||S.O.|
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
L’ISS Governance QualityScore de Hologic, Inc. en date du 1 février 2023 est 6. Les scores principaux sont Audit : 4; Société : 9; Droits des actionnaires : 7; Compensation : 4.